Skip to main content

Table 4 Associations between tumor and patient characteristics, SNPs, and pCR in breast and lymph nodes

From: Insulin-like growth factor 1 receptor expression and IGF1R 3129G > T polymorphism are associated with response to neoadjuvant chemotherapy in breast cancer patients: results from the NEOZOTAC trial (BOOG 2010-01)

    

Univariate analysis

Multivariate analysis

Parameter

 

N

% pCR

OR

95 % CI

P value

OR

95 % CI

P value

Clinical T stage

cT1/cT2

106

17.9

1

Reference

 

1

Reference

 
 

cT3/T4

73

6.8

0.34

0.12–0.95

0.039

0.49

0.16–1.50

0.209

Clinical N stage

cN0

84

21.4

1

Reference

 

1

Reference

 
 

cN+

95

6.3

0.25

0.09–0.66

0.005

0.19

0.06–0.58

0.003

HR status

ER+ and/or PR+

151

8.6

1

Reference

 

1

Reference

 
 

Triple negative

28

39.3

6.87

2.66–17.7

0.00007

9.35

3.09–28.3

0.00008

Allocated treatment

TAC + ZA

87

14.9

1

Reference

0.559

   

TAC only

92

12.0

0.77

0.33–1.83

    

Age

   

0.96

0.89–1.09

0.186

   

BMI

   

0.97

0.88–1.08

0.581

   

rs10735380

AA

97

13.4

1

Reference

    

IGF1

AG

66

13.6

1.02

0.41–2.55

0.966

   
 

GG

5

20.0

1.61

0.17–15.6

0.679

   

rs1520220

CC

111

15.3

1

Reference

    

IGF1

CG

45

13.3

0.85

0.31–2.32

0.752

   
 

GG

11

0.0

   

rs6220

AA

88

11.4

1

Reference

    

IGF1

AG

56

16.1

1.49

0.57–3.94

0.418

   
 

GG

17

17.6

1.67

0.41–6.48

0.475

   

rs2270628

CC

101

11.9

1

Reference

    

IGFBP3

CT

45

17.8

1.60

0.61–4.24

0.342

   
 

TT

9

0.0

   

rs2854746

GG

55

7.3

1

Reference

 

1

Reference

 

IGFBP3

GC

72

16.7

2.55

0.78–8.40

0.124

3.06

0.82–11.4

0.097

 

CC

33

21.2

3.43

0.92–12.8

0.066

4.02

0.92–17.6

0.065

 

GG

55

7.3

1

Reference

 

1

Reference

 
 

GC/CC

105

18.1

2.82

0.91–8.74

0.073

3.35

0.96–11.7

0.058

rs4320932

TT

106

15.1

1

Reference

    

IGF2

TC

57

12.3

0.79

0.30–2.04

0.623

   
 

CC

8

12.5

0.80

0.09–6.98

0.843

   

rs2016347

GG

45

4.4

1

Reference

 

1

Reference

 

IGF1R

GT

94

17.0

4.41

0.97–20.1

0.055

5.58

1.08–28.7

0.040

 

TT

32

15.6

3.98

0.72–22.0

0.113

6.67

1.03–43.1

0.046

 

GG

45

4.4

1

Reference

 

1

Reference

 
 

GT/TT

126

16.7

4.30

1.00–19.1

0.056

5.82

1.17–29.1

0.032

  1. BMI body mass index, CI confidence interval, ER estrogen receptor, HR hormone receptor, IGF insulin-like growth factor 1, IGFBP3 insulin-like growth factor binding protein 3, IGF1R insulin-like growth factor 1 receptor, OR odds ratio, pCR pathological complete response, PR progesterone receptor, SNP single nucleotide polymorphism, TAC docetaxel, doxorubicin, cyclophosphamide, ZA zoledronic acid